Improvement of metabolic control after 3-month use of real-time continuous glucose monitoring in patients with type 1 diabetes: a multicenter study in Greece
| Autor: | Emmanuel Pangalos, Andriani Gerasimidi-Vazeou, Eleni Anastasiou, Agathocles Tsatsoulis, Charalampos Vasilopoulos, Marianna Benroubi, Nikolaos Tentolouris, Ioanna Eleftheriadou, Christos Zoupas, Christos Manes, Triantafyllos Didangelos, Angelos C Pappas, Petros Thomakos |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Insulin pump
Adult Blood Glucose Male medicine.medical_specialty endocrine system diseases Adolescent Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism 030204 cardiovascular system & hematology 03 medical and health sciences Young Adult 0302 clinical medicine Insulin Infusion Systems Diabetes mellitus Internal medicine Clinical endpoint Product Surveillance Postmarketing Medicine Humans Hypoglycemic Agents Glycemic Glycated Hemoglobin Type 1 diabetes business.industry Insulin Blood Glucose Self-Monitoring nutritional and metabolic diseases General Medicine Middle Aged medicine.disease Hypoglycemia Ketoacidosis Diabetes Mellitus Type 1 Metabolic control analysis Patient Compliance Female business |
| Zdroj: | Hormones (Athens, Greece). 18(4) |
| ISSN: | 2520-8721 |
| Popis: | To assess the efficacy of a real-time continuous glucose monitoring (RT–CGM) system added to insulin pump therapy for 3 months, in sub-optimally controlled adults with type 1 diabetes mellitus (T1D). This was a prospective, multicenter, non-randomized, post-market release study. A total of 43 adult patients with T1D on insulin pump therapy and inadequate glycemic control (HbA1c > 7.0%) participated in the study. The primary endpoint was the change from baseline HbA1c levels. Secondary objectives were to evaluate the impact of the RT–CGM system on glucose variability, daily insulin requirements, and the frequency of hypoglycemic and ketoacidosis events. At 3 months, the baseline HbA1c values decreased from 8.0 (7.6, 8.7) to 7.1 (6.7, 8.0) % (p < 0.001). Nineteen participants (44.2%) had a posttreatment HbA1c level ≤ 7%. Average total daily insulin requirements, as well as the average number of insulin boluses per day, increased significantly after the use of the RT–CGM system. The number of hypoglycemic events recorded did not differ between the first week and last week of RT–CGM usage, while no severe hypoglycemic episodes, ketoacidosis events, or hospitalizations related to diabetes occurred during the 3-month follow-up period. Addition of a RT–CGM system to insulin pump therapy for 3 months in inadequately controlled patients with T1D resulted in improved HbA1c levels, without increasing the risk of hypoglycemic events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink